What is HC Wainwright’s Estimate for OTLK Q1 Earnings?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Outlook Therapeutics in a research report issued to clients and investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($0.21) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS and FY2029 earnings at $3.24 EPS.

A number of other equities analysts have also recently weighed in on the company. Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research dropped their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Finally, Chardan Capital reissued a “neutral” rating and issued a $3.00 price target on shares of Outlook Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Outlook Therapeutics Trading Down 0.9 %

Shares of OTLK opened at $1.70 on Wednesday. The business’s 50-day moving average price is $1.88 and its 200 day moving average price is $4.35. The stock has a market capitalization of $54.21 million, a P/E ratio of -0.23 and a beta of 0.58. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, February 14th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.04).

Hedge Funds Weigh In On Outlook Therapeutics

A number of large investors have recently made changes to their positions in OTLK. Russell Investments Group Ltd. increased its holdings in shares of Outlook Therapeutics by 34,936.7% in the 4th quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock valued at $32,000 after purchasing an additional 17,119 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Outlook Therapeutics in the 4th quarter valued at about $48,000. Jane Street Group LLC increased its holdings in shares of Outlook Therapeutics by 133.9% in the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company’s stock valued at $50,000 after purchasing an additional 15,008 shares during the period. Christensen King & Associates Investment Services Inc. acquired a new position in shares of Outlook Therapeutics in the 3rd quarter valued at about $55,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Outlook Therapeutics by 44.8% in the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company’s stock valued at $56,000 after purchasing an additional 9,211 shares during the period. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.